Skip to main navigation Skip to search Skip to main content

Phase II Double-Blind, Placebo-Controlled, Randomized, Efficacy and Safety Study of Subcutaneously Administered HER-096 in Patients with Mild to Moderate Parkinson’s Disease

Project Details

AcronymHERMOD
StatusActive
Effective start/end date1/06/26 → 31/05/30

Funding

  • European Commission: €7,992,761.25